Triptorelin for the treatment of adenomyosis: A multicenter observational study of 465 women in Russia

What Was Tested

Researchers studied Triptorelin in this observational study publication.

The researchers performed a medical record review, interviews to assess symptom severity, and pelvic assessments including transvaginal ultrasound.

Who Took Part

The study group was 28 women.

By PubMed's age tags, the people studied were adults, women only.

How the Study Was Run

In design terms this was an open-label and multicenter study.

Everyone knew when Triptorelin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Running at several centres spread the Triptorelin study over different clinics and patient groups.

Data were obtained at first injection of triptorelin (visit 1), on the day of last injection (visit 2), 6 months after last injection (visit 3), and 9 months after last injection (visit 4).

What Was Measured

The subject headings attached to it are Adenomyosis, Dysmenorrhea, Endometriosis, Menorrhagia, Pelvic Pain, Reproductive Health and Russia.

Author keywords: Dysfunctional uterine bleeding, Fertility, Pregnancy and Triptorelin.

What This Means in Plain Language

The paper is an open-label and multicenter study of Triptorelin in 28 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics), a journal based in United States.

More context: the Triptorelin compound page, all human trials.